2026 Edison Awards | Health, Medical & Biotech — Precision Health Technologies

The human body has always had the ability to heal itself. Bones knit, tendons repair, and cartilage regenerates. This sometimes happens slowly, or imperfectly, but it happens with a biological intelligence that medicine has spent decades trying to harness rather than replace. Regenerative medicine is the field built on that premise: that the most powerful healing agents are often the ones already present in your own blood, concentrated, targeted, and delivered where they are needed most. And few therapies embody that premise more directly than platelet-rich plasma (PRP) a biologic concentrate derived from a patient’s own blood and used across orthopedics, sports medicine, aesthetics, dentistry, and wound care to accelerate tissue repair and recovery.

The scale of need driving this field is significant. Musculoskeletal disorders now affect approximately 1.69 billion people globally, according to 2021 Global Burden of Disease data, representing the leading cause of non-fatal disability worldwide and generating 161.9 million disability-adjusted life years. Osteoarthritis alone affects over 500 million people, with prevalence rising sharply as populations age. Against that backdrop, the global PRP market is projected to grow from $647 million in 2025 to $1.76 billion by 2034, driven by rising demand for non-surgical, minimally invasive regenerative treatments — with autologous PRP, derived from the patient’s own blood, holding the largest share of that market at approximately 86%.

The challenge has never been the biology. The challenge has been the engineering: how to reliably capture, concentrate, and deliver the biologics that make PRP therapy effective, with precision and consistency in a clinical setting. EmCyte Corporation, a Fort Myers, Florida-based medical device company with two decades of experience in regenerative medicine, has spent years solving exactly that problem. Their Pure SupraPhysiologic™ Concentrating System with AspiraDome™ Technology was recognized with a 2026 Edison Award in the Precision Health Technologies subcategory, and it represents a meaningful leap forward in what point-of-care biologic preparation can achieve.

The Engineering Challenge Inside Every PRP Procedure

To understand what EmCyte has built, it helps to understand what PRP processing actually requires. A clinician draws a patient’s blood, spins it in a centrifuge to separate its components by density, and then aspirates the fraction known as the buffy coat. This is a thin, visually subtle layer sitting between the red blood cells below and the platelet-poor plasma above. That buffy coat contains the platelets, monocytes, and progenitor cells that give PRP its regenerative properties. Capturing it accurately, without contaminating the concentrate with red blood cells from below or diluting it with platelet-poor plasma from above, is the central precision challenge of every PRP preparation.

In practice, that capture has historically depended on the clinician’s experience and judgment, the quality of their visualization, and the limitations of the aspiration interface between the syringe and the separated layers. Small errors in aspiration angle, depth, or timing translate directly into variability in the biologic output, meaning fewer platelets, more red blood cell contamination, less consistent clinical outcomes.

What AspiraDome™ Changes

EmCyte’s answer to that challenge is a patented dome-shaped aspiration interface called AspiraDome™, which is a design innovation that transforms the aspiration step from a manual judgment call into a guided, reproducible process.

The dome geometry is the key. Rather than a flat or angled interface that can shift or tilt during aspiration, the AspiraDome™ maintains a consistent, centered contact with the buffy coat layer regardless of slight variations in tube angle or clinician handling. As EmCyte describes it, the design offers “better visualization, more accurate buffy coat capture, and less red blood cell contamination,” delivering each of those benefits not through technique, but through the physical design of the device itself.

The Pure SupraPhysiologic™ System pairs AspiraDome™ with a double-spin, single-device platform incorporating variable chamber technology and active disc displacement to standardize cellular separation across the full processing workflow. The result is a system where the variability that traditionally lived in the hands of the clinician has been systematically reduced by engineering. Platelet yields reach over 80% in leukocyte-poor preparations and over 90% in monocyte- and neutrophil-rich formulations. Red blood cell contamination in leukocyte-poor PRP is maintained below 1% HCT s— a level of purity that EmCyte notes “creates a clean, regenerative environment ideal for healing soft tissue and joints” and reduces the potential for post-treatment inflammation and oxidative stress.

Monocyte-rich PRP is a formulation that has attracted significant clinical research interest for its role in promoting M2 macrophage polarization, which shifts tissue environments from inflammation toward repair, angiogenesis, and regeneration, and achieves monocyte capture rates up to 90%. For clinicians treating conditions where modulating the inflammatory response is as important as delivering platelets, that precision matters enormously.

The system also eliminates the flip vent step that complicated earlier generation devices, a workflow simplification that reduces both processing time and the risk of user error, and makes the system more accessible to a broader range of clinical settings and experience levels.

From Variability to Consistency: Why This Matters at Scale

The implications of reducing PRP variability extend well beyond any individual procedure. One of the persistent challenges in PRP research has been the difficulty of comparing outcomes across studies and clinical settings, because PRP preparations vary so widely in platelet concentration, leukocyte content, and activation state depending on the device and technique used. A system that delivers consistent, high-yield, low-contamination biologics every time is not only better for the patient on the table, it is better for the field’s ability to generate reliable clinical evidence.

Autologous PRP therapies have seen a dramatic increase in use for orthopedic conditions over the past five years, expanding into knee arthritis, hip joint arthritis, shoulder arthritis, ankle arthritis, and a growing range of soft tissue applications. As clinical adoption accelerates globally — across Asia-Pacific, Europe, and Latin America, where regenerative medicine infrastructure is growing rapidly — the demand for devices that can deliver consistent, high-quality biologics at the point of care will only intensify.

EmCyte’s Pure SupraPhysiologic™ System is available in 60 mL and 120 mL configurations, with options to integrate the CORE™ Protein Concentrating System for enhanced biologic performance in cases where exosome and growth factor concentration is a clinical priority.

A Company Built on the Science It Sells

EmCyte is not a large-scale medical device conglomerate. It is a specialist, founded on deep expertise in autologous biologics and regenerative medicine, with a product portfolio including PurePRP SP™, PureBMC SP™, CORE™, and the Sapphire Centrifuge. This company is built around a single organizing philosophy: that the quality of the biologic concentrate is the foundation of the clinical outcome.

That philosophy extends into education. Through BioEdge Musculoskeletal Training and the Gulf Coast Biologics programs, EmCyte invests in helping clinicians not just use their technology but understand the science behind it — from buffy coat biology to growth factor delivery to the evidence base for different PRP formulations across different clinical indications.

That commitment to the broader regenerative medicine community was on display at the 2026 Edison Awards, where EmCyte hosted attendees of the Lewis Latimer Fellowship Program at their Southwest Florida facility, an experience that gave the next generation of diverse innovators a firsthand look at how medical device innovation moves from concept to clinical reality.

The Future of Healing, Standardized

Regenerative medicine’s promise has always been its logic: use the body’s own biology, concentrated and precisely delivered, to accelerate healing that would otherwise happen too slowly or incompletely. The gap between that promise and clinical reality has historically been the variability of the tools used to prepare and deliver the biologics.

EmCyte’s Pure SupraPhysiologic™ System with AspiraDome™ Technology closes that gap. It does so not by introducing a new biology, but by building the engineering precision around an existing one — making high-yield, low-contamination, reproducible biologic preparation accessible at the point of care for a broad range of clinicians, in a broad range of settings, for a broad range of patients whose bodies already have the capacity to heal.

Learn more about the Pure SupraPhysiologic™ System and AspiraDome™ Technology at emcyte.com, and explore the full 2026 Edison Awards winners at edisonawards.com.